Cyclohexyl-griselimycin Is Active against Mycobacterium abscessus in Mice.
Antimicrob Agents Chemother
; 66(1): e0140021, 2022 01 18.
Article
en En
| MEDLINE
| ID: mdl-34723632
ABSTRACT
Cyclohexyl-griselimycin is a preclinical candidate for use against tuberculosis (TB). Here, we show that this oral cyclodepsipeptide is also active against the intrinsically drug-resistant nontuberculous mycobacterium Mycobacterium abscessus in vitro and in a mouse model of infection. This adds a novel advanced lead compound to the M. abscessus drug pipeline and supports a strategy of screening chemical matter generated in TB drug discovery efforts to fast-track the discovery of novel antibiotics against M. abscessus.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Mycobacterium abscessus
/
Infecciones por Mycobacterium no Tuberculosas
Límite:
Animals
Idioma:
En
Revista:
Antimicrob Agents Chemother
Año:
2022
Tipo del documento:
Article
País de afiliación:
Estados Unidos